ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO455

Diagnostic Efficacy of sPLA2R-Ab for Membranous Nephropathy in Diabetes Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Wang, Qian, Chinese PLA General Hospital, Beijing, China
  • Dong, Zheyi, Chinese PLA General Hospital, Beijing, China
  • Chen, Xiangmei, Chinese PLA General Hospital, Beijing, China
  • Liu, Xiaomin, Chinese PLA General Hospital, Beijing, China
  • Zhang, Weiguang, Chinese PLA General Hospital, Beijing, China
Background

The pathological types of diabetes kidney disease (DKD) are various, among which, membranous nephropathy(MN) accounts for a large proportion of non-diabetic renal diseases (NDRD).Serum anti-phospholipidase A2 receptor antibody(sPLA2R-Ab) is used for the diagnosis of MN, the diagnostic efficacy of sPLA2R-Ab for MN in DKD need to be further verified.

Methods


Screened on patients with type 2 diabetes mellitus who underwent a renal biopsy and had a valid sPLA2R-Ab test results,hospitalized in the general hospital of the people's liberation army of China between May 1st, 2016 and January 30th, 2018. Eligible patients were divided into two groups according to the pathological results: MN group and non-MN group.Patients’clinical characteristics and laboratory datas were collected.

Results


The study included 252 patients:59 (23.4%) in the MN group and 193 (76.6%) in the non-MN group. The baseline were compared between the two groups: age, history of diabetes, creatinine, GFR and blood pressure were statistically significant.MN group was older, lower blood pressure, shorter history of diabetes and better renal function than non-MN group. The positive value of SPLA2R-Ab was defined respectively as≥20, > 12, > 2: sPLA2R-Ab achieved a good diagnostic efficiency with sensitivity of 59.3%, 66.1% and 83.1% , specificity of 100%, 98.96% and 93.26%, positive predictive values of 100%, 95.12% and 79.0%, negative predictive values of 88.9%, 90.52% and 94.74% ,and accuracy of 90%, 91.27% and 90.87% for MN in DKD respectively.

Conclusion

SPLA2R-Ab has a good diagnostic accuracy for MN in DKD, and the positive threshold may be reduced to 12, which can increase the accuracy of diagnosis.

Table1 The diagnostic efficacy of sPLA2R-Ab for MN in DKD
positive threshold sPLA2R-Abrenal pathological renal pathological Total
  MNnon-MN 
≥20positive35035
≥20negative24193217
≥20Total59193252
>12positive39241
>12negative20191211
>12Total59193252
>2positive491362
>2negative10180190
>2Total59193252